Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(2015) In Leukemia & Lymphoma 56(5). p.1385-1391- Abstract
- Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the... (More)
- Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was (sic)52 700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to (sic)22 700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7791118
- author
- Ohm, Lotta ; Lundqvist, Adam ; Dickman, Paul ; Hoglund, Martin ; Persson, Ulf LU ; Stenke, Leif ; Carlsson, Katarina Steen and Bjorkholm, Magnus
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chronic myeloid leukemia, survival, population-based, costs, imatinib, lifetime simulation
- in
- Leukemia & Lymphoma
- volume
- 56
- issue
- 5
- pages
- 1385 - 1391
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000356532000047
- scopus:84932148793
- pmid:25139694
- ISSN
- 1042-8194
- DOI
- 10.3109/10428194.2014.953141
- language
- English
- LU publication?
- yes
- id
- 5aeda821-e0e8-4cf5-86e4-c1ff6e873287 (old id 7791118)
- date added to LUP
- 2016-04-01 14:08:53
- date last changed
- 2022-04-22 01:34:11
@article{5aeda821-e0e8-4cf5-86e4-c1ff6e873287,
abstract = {{Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was (sic)52 700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to (sic)22 700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.}},
author = {{Ohm, Lotta and Lundqvist, Adam and Dickman, Paul and Hoglund, Martin and Persson, Ulf and Stenke, Leif and Carlsson, Katarina Steen and Bjorkholm, Magnus}},
issn = {{1042-8194}},
keywords = {{Chronic myeloid leukemia; survival; population-based; costs; imatinib; lifetime simulation}},
language = {{eng}},
number = {{5}},
pages = {{1385--1391}},
publisher = {{Taylor & Francis}},
series = {{Leukemia & Lymphoma}},
title = {{Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib}},
url = {{http://dx.doi.org/10.3109/10428194.2014.953141}},
doi = {{10.3109/10428194.2014.953141}},
volume = {{56}},
year = {{2015}},
}